Literature DB >> 25760751

[Clinical practice guideline. Diagnosis and treatment of postmenopausal and perinemopausia].

Alberto Alvarado-García1, Tomás Hernández-Quijano, Marcelino Hernández-Valencia, Miriam Concepción Negrín-Pérez, Brendha Ríos-Castillo, Gregorio Urbano Valencia-Pérez, Víctor Saúl Vital-Reyes, María Antonia Basavilvazo-Rodríguez, Laura Pilar Torres-Arreola, Guillermo Federico Ortiz-Luna, Fernando Sánchez-Aguirre, Armando Montaño-Uscanga.   

Abstract

Post-menopause is the period of life where a deep decline occurs in circulating estrogen levels, inducing the appearance of psycho and somatic symptoms. The classification to understand the chronology of reproductive aging in women (known as STRAW) determines the clinical and endocrine changes contemplating menstrual cycles, symptoms, measurements of FSH, LH, inhibin B, anti-Mullerian hormone , and follicular account. The diagnosis of menopause is established by the absence of menstruation for 12 months or more. The most frequent clinical manifestations of the climacteric syndrome transition to menopause are menstrual disorders, vasomotor symptoms (flushes and/or sweats) and genitourinary manifestations. The assessment of women in the peri- or postmenopause aims to develop: cervicovaginal cytology , lipid profile , serum glucose, basal Mammography at least a year before, pelvic ultrasound, urinalysis, serum TSH, Densitometry in patients older than 60 years if there is no recourse can be applied and FRAX. Drug therapy for the treatment of disorders of the transition to menopause or menopause is divided into: hormone therapy (HT) based estrogens and progestin hormone not being the most recommended the serotonin reuptake inhibitors and norepinephrine, clonidine, gabapentin or veralipride.

Entities:  

Keywords:  Aging; Menopause; Postmenopausal

Mesh:

Year:  2015        PMID: 25760751

Source DB:  PubMed          Journal:  Rev Med Inst Mex Seguro Soc        ISSN: 0443-5117


  3 in total

1.  CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice.

Authors:  Kun Zhang; Qi Yang; Le Yang; Yan-Jiao Li; Xin-Shang Wang; Yu-Jiao Li; Rui-Li Dang; Shao-Yu Guan; Yan-Yan Guo; Ting Sun; Yu-Mei Wu; An Liu; Yan Zhang; Shui-Bing Liu; Ming-Gao Zhao
Journal:  J Clin Invest       Date:  2019-05-06       Impact factor: 14.808

2.  Evaluation of the clinical application of a leaflet for clinical practice guidelines in patients with herniated intervertebral discs: a study protocol for a randomized controlled trial.

Authors:  Ju Ah Lee; Jiae Choi; Tae-Young Choi; Ji Hee Jun; In-Hyuk Ha; Myeong Soo Lee
Journal:  Integr Med Res       Date:  2016-04-13

3.  A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways.

Authors:  Ying Liu; Wenjie Liu; Ziqiang Yu; Yan Zhang; Yinghua Li; Dantao Xie; Gang Xie; Li Fan; Shipeng He
Journal:  Cell Death Dis       Date:  2021-06-26       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.